1. Residual risk of major adverse cardiovascular and limb events among different atherosclerotic cardiovascular disease phenotypes receiving guideline-recommended antiplatelet monotherapy: The resrisk study. (August 2022) Authors: Vallejo-Vaz, A.J.; Dharmayat, K.I.; Nzeakor, N.; Carrasco, C.P.; Fatoba, S.T.; Fonseca, M.J.; Tolani, E.; Lee, C.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗